为中国第二阶段固态肿瘤临床试验核准的生物药用EAL细胞免疫疗法药物。 Immunotech Biopharm's EAL cellular immunotherapy drug approved for China's Phase II clinical trials for solid tumors.
中国制药公司Immunotech生物药厂生产细胞免疫疗法药物“扩大活性淋巴细胞(EAL)”,经批准用于中国固态肿瘤的第二阶段临床试验。 Immunotech Biopharm, a Chinese pharma firm, produces cellular immunotherapy drug, Expanded Activated Lymphocytes (EAL), approved for China's second-phase clinical trials for solid tumors. 这是首家开发细胞免疫疗法产品的国内制药公司, 于2020年在香港证券交易所上市。 Founded in 2006, it's the first domestic pharmaceutical company to develop cellular immunotherapy products, going public on the Hong Kong Stock Exchange in 2020. 该公司的北京设施是中国最大的此类设施,涵盖30,000平方米。 The company's Beijing facility is the largest of its kind in China, covering 30,000 sqm. 其增长是中国生物制药部门快速发展的一部分,自2021-2025年以来,主要商业收入年均增长9.3%。 Its growth is part of China's rapid advancements in the biopharmaceutical sector, with main business revenues growing at an annual average of 9.3% since 2021-2025.